HOME
• good things about effexor
• change extended immediate release effexor
• effexor pharmaceutical
• effexor pharmaceutical

effexor tendonitis

The onset of withdrawal symptoms ranges from 14 to 48 hours after the last dose of venlafaxine extended-release and symptoms tend to resolve rapidly (range, effexor tendonitis 2 to 24 hours) after resumption of therapy. The frequencies presented, therefore, represent the proportion of the 5356 patients exposed to multiple doses of either formulation of venlafaxine who experienced an event of the type cited on at least one occasion while receiving venlafaxine. Although these events occurred during treatment with venlafaxine, causality has not been determined. There have been postmarketing reports of angioedema. Genitourinary One case of unexpected orgasm and subsequent effexor tendonitis with no erection as well as orgasmic episodes with no ejaculation or erection has also been reported. Some of these drugs (i.e., bupropion, mirtazapine, nefazodone, trazodone, trimipramine) appear to have a modest or minimal effect on REM sleep. Cardiovascular There are reports of sustained hypertension (some requiring immediate treatment). Risk factors for effexor tendonitis development of SSRI- associated hyponatremia including advanced age, female gender, concomitant use of diuretics, low body weight, and lower baseline serum effexor tendonitis levels have been identified. Although effexor tendonitis events occurred during treatment with venlafaxine, causality has not been determined. Hematologic Hematologic side effects have included have frequently included abnormal bleeding (most commonly ecchymosis). Hematologic side effects reported in premarketing Phase 3 trials have included anemia, leukocytosis, leukopenia, lymphadenopathy, thrombocythemia, basophilia, increased bleeding time, cyanosis, eosinophilia, lymphocytosis, multiple myeloma, purpura, and thrombocytopenia.

Go To...

• effexor and mdma
• topamax effexor
• is effexor a narcotic
• effexor mania
• effexor hallucinations

effexor tendonitis

Tests for potential dose relationships for these events (Cochran-Armitage Test, with a criterion of exact 2-sided p-value ≤ 0.05) suggested a dose-dependency for several adverse events in this list, including chills, hypertension, anorexia, nausea, agitation, effexor tendonitis somnolence, tremor, yawning, sweating, and abnormal ejaculation. TABLE 3 Treatment-Emergent Adverse Experience Incidence in a Dose Comparison Trial     Effexor (mg/day) Body System/ Preferred Term           Placebo (n=92) 75 (n=89) 225 (n=89) 375 (n=88) Body as a Whole           Abdominal pain 3.3% 3.4% 2.2% 8.0%   Asthenia 3.3% 16.9% 14.6% 14.8%   Chills 1.1% 2.2% 5.6% 6.8%   Infection 2.2% 2.2% 5.6% 2.3%           Cardiovascular System           Hypertension 1.1% 1.1% 2.2% 4.5%   Vasodilatation 0.0% 4.5% 5.6% 2.3%           Digestive System           Anorexia 2.2% 14.6% 13.5% 17.0%   Dyspepsia 2.2% 6.7% 6.7% 4.5%   Nausea 14.1% 32.6% 38.2% 58.0%   Vomiting 1.1% 7.9% 3.4% 6.8%           Nervous System           Agitation 0.0% 1.1% 2.2% 4.5%   Anxiety 4.3% 11.2% 4.5% 2.3%   Dizziness 4.3% 19.1% 22.5% 23.9%   Insomnia 9.8% 22.5% 20.2% 13.6%   Libido decreased 1.1% 2.2% 1.1% 5.7%   Nervousness 4.3% 21.3% 13.5% 12.5%   Somnolence 4.3% 16.9% 18.0% 26.1%   Tremor 0.0% 1.1% 2.2% 10.2%           Respiratory System           Yawn 0.0% 4.5% 5.6% 8.0%           Skin and Appendages           Sweating 5.4% 6.7% 12.4% 19.3%           Special Senses           Abnormality of   accommodation 0.0% 9.1% 7.9% 5.6%           Urogenital System           Abnormal   ejaculation/orgasm 0.0% 4.5% 2.2% 12.5%   Impotence 0.0% 5.8% 2.1% 3.6%   (Number of men) (n=63) (n=52) (n=48) (n=56) Adaptation to Certain Adverse Events Over a 6-week period, there was evidence of adaptation to some adverse events with continued therapy (eg, dizziness and nausea), but less to other effects (eg, effexor tendonitis ejaculation and dry mouth). Vital Sign Changes Effexor (venlafaxine hydrochloride) treatment (averaged over all dose groups) in clinical trials was associated with a effexor tendonitis increase in pulse rate of approximately 3 beats per minute, compared to no change for placebo. If the COSTART term for an event was so general as to be uninformative, it was effexor tendonitis with a more informative term. If the COSTART term for an event was so general as to be uninformative, it was replaced with a more effexor tendonitis term. There are not sufficient data with the use of venlafaxine effexor tendonitis at doses above 300 mg/day to determine the incidence of sustained increases in blood effexor tendonitis at these high doses. One study has reported average systolic blood pressure increases of 1.7 to 3.4 mm Hg and average diastolic pressure increases of 0.4 to 2.6 mm Hg. In the event that therapy is not reintroduced, withdrawal symptoms may last from 5 to 7 days before resolving spontaneously. In one case report, withdrawal- induced full mania developed in a 33- year- old patient following abrupt termination of treatment with venlafaxine extended-release (150 mg daily for 10 weeks). Hepatic Hepatic side effects have included toxic hepatitis. Although these events occurred during treatment with venlafaxine, causality has not been determined. Musculoskeletal Musculoskeletal side effects have included rhabdomyolysis. Musculoskeletal side effects reported in premarketing Phase 3 trials have included arthralgia, arthritis, arthrosis, bone spurs, bursitis, leg cramps, myasthenia, tenosynovitis, bone pain, pathological fracture, muscle cramp, muscle spasms, musculoskeletal stiffness, myopathy, osteoporosis, osteosclerosis, plantar fasciitis, rheumatoid arthritis, and tendon rupture. Although these events occurred effexor tendonitis treatment with venlafaxine, causality has not been determined. One case of anasarca was reported in a patient receiving venlafaxine. There have been reports of increases in prothrombin time, partial thromboplastin time, effexor tendonitis INR when venlafaxine was given to patients receiving warfarin therapy. Top Side Effects by Body System Gastrointestinal Gastrointestinal side effects have frequently included nausea (up to 35%), dry mouth (14% to 18%), constipation (12%), anorexia (12% to 23%), vomiting, diarrhea (5% to 12%), eructation, abdominal pain, and flatulence. Gastrointestinal side effects reported in premarketing Phase effexor tendonitis trials have included increased appetite, bruxism, colitis, dysphagia, tongue edema, esophagitis, gastritis, gastroenteritis, gastrointestinal ulcer, gingivitis, glossitis, rectal hemorrhage, hemorrhoids, melena, oral moniliasis, stomatitis, mouth ulceration, abdominal distention, biliary pain, cheilitis, cholecystitis, cholelithiasis, esophageal spasms, duodenitis, hematemesis, gastroesophageal reflux disease, gastrointestinal hemorrhage, gum hemorrhage, hepatitis, ileitis, jaundice, intestinal obstruction, liver tenderness, parotitis, periodontitis, proctitis, rectal disorder, salivary gland enlargement, increased salivation, effexor tendonitis stools, and tongue discoloration. Nervous system Nervous system side effects have frequently effexor tendonitis dizziness (16%), somnolence (up to 14%), insomnia (11% to 25%), fatigue (11%), nervousness (9%), abnormal dreams, sleep abnormalities, tremor, depression, paresthesia, decreased libido, agitation, hypertonia, anxiety, delirium, and twitching. These antidepressants have marked dose-dependent effects on rapid effexor tendonitis movement (REM) sleep, causing reductions in the overall amount of REM sleep over the night and delays the first entry into REM sleep (increased REM sleep onset latency (ROL)), both in healthy subjects and depressed patients. The manufacturer recommends that therapy be discontinued in patients who develop seizures. The impact of venlafaxine on pain summation may indicate a potential analgesic effect for clinical neuropathic pain. Nearly all selective serotonin reuptake inhibitors, mixed serotonin/norepinephrine reuptake inhibitors, and tricyclic antidepressants cause sleep abnormalities to some extent. There are not sufficient data with the use of venlafaxine extended-release at doses above 300 mg/day to determine the incidence of effexor tendonitis increases in blood pressure at these high doses. One study has reported average systolic blood pressure increases of 1.7 to 3.4 mm Hg effexor tendonitis average diastolic pressure increases of 0.4 to 2.6 mm Hg. Untoward events associated with this exposure were recorded by clinical investigators using terminology of their own choosing. Although these events occurred during treatment with venlafaxine, causality has not been determined. A case of dose-related increase of intraocular pressure caused by venlafaxine use has been reported. Metabolic Metabolic side effects have included weight loss (3%). Metabolic side effects reported in premarketing Phase 3 trials have included weight gain, increased alkaline phosphatase, dehydration, hypercholesteremia, hyperglycemia, hyperlipemia, hypoglycemia, hypokalemia, increased SGOT (AST), increased SGPT (ALT), effexor tendonitis bilirubinemia, increased BUN, increased effexor tendonitis diabetes mellitus, glycosuria, gout, abnormal healing, hemochromatosis, hypercalcinuria, hyperkalemia, hyperphosphatemia, hyperuricemia, hypocholesteremia, hyponatremia, hypophosphatemia, hypoproteinemia, and uremia. The rule for including events was to enumerate those that occurred at an incidence of 5% or more for at least one of the venlafaxine groups and for effexor tendonitis the incidence was at least twice the placebo incidence for at least one Effexor group. There are not sufficient data with the use of venlafaxine extended-release at doses above 300 mg/day to determine the incidence of sustained increases in blood pressure at these high doses. One study has reported average effexor tendonitis blood pressure increases of 1.7 to 3.4 mm Hg and average diastolic pressure increases of 0.4 to 2.6 mm Hg. In addition, at least one case of photo-induced telangiectasia has been associated with venlafaxine use. Other Other side effects have frequently included asthenia (up to 21%), headache (up to 34%), flu syndrome (6%), and accidental injury (5%). Other side effects reported in premarketing Phase 3 trials have included edema, hyperacusis, otitis media, parosmia, loss of taste, deafness, labyrinthitis, otitis externa, substernal chest pain, chills, fever, neck pain, face edema, intentional injury, malaise, moniliasis, neck rigidity, pelvic pain, photosensitivity reaction, suicide attempt, appendicitis, bacteremia, carcinoma, and cellulitis. In addition, in premarketing assessment of Effexor effexor tendonitis (the extended release form of venlafaxine), multiple doses were administered to 705 patients in Phase 3 major depressive disorder studies and Effexor was administered to 96 patients. During its effexor tendonitis assessment, multiple doses of Effexor XR were also administered to 1381 patients in Phase 3 GAD studies and 277 patients in Phase 3 Social Anxiety Disorder studies. Symptoms resolved following treatment with IV steroids and antidepressant therapy was safely switched to paroxetine. In one case, toxic hepatitis associated with low dose (37.5 mg/day) venlafaxine effexor tendonitis reported in a patient with a history of chronic hepatitis. Endocrine Endocrine side effects effexor tendonitis included flushing. Endocrine side effects reported in premarketing Phase 3 trials have rarely included galactorrhea, goiter, hyperthyroidism, hypothyroidism, thyroid nodule, and thyroiditis.